All In Biotech

NDA 020596 · Viiv Hlthcare

Epivir

Lamivudine · Oral · Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Accelerated approvalPriority review

Last checked: Nov 19, 2026Latest source record: May 10, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1995

Nov 17, 1995

Approved uses

6

Original approval plus efficacy supplements

Registered trials

737

226 Phase 3, 25 recruiting

FAERS reports

30,839

29,623 serious, 4,112 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: EXACERBATIONS OF HEPATITIS B and DIFFERENT FORMULATIONS OF EPIVIR Exacerbations of Hepatitis B Severe acute exacerbations of hepatitis B have been reported in patients who are co-infected with hepatitis B virus (HBV) and human immunodeficiency virus (HIV-1) and have discontinued EPIVIR. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue EPIVIR and are co-infected with HIV-1 and HBV. If appropriate, initiation of anti-hepatitis B therapy may be warranted [see Warnings and Precautions ( 5.1 )]. Important Differences among Lamivudine-Containing Products EPIVIR tablets and oral solution (used to treat HIV-1 infection) contain a higher dose of the active ingredient (lamivudine) than EPIVIR-HBV tablets and oral solution (used to treat chronic HBV infection). Patients with HIV-1 infection...

What it is approved for

From the label in effect Aug 15, 2024.

EPIVIR is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV‑1) infection. Limitations of Use: • The dosage of this product is for HIV‑1 and not for HBV. EPIVIR is a nucleoside analogue reverse transcriptase inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV‑1 infection. Limitations of Use: The dosage of this product is for HIV‑1 and not for HBV. ( 1 )

Mechanism: Lamivudine is an antiretroviral agent [see Microbiology ( 12.4 )].

Therapeutic areas: Infectious disease and vaccines · Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • EPIVIR · LAMIVUDINE 10MG/ML · SOLUTION, ORAL · Prescription · TE AA

Clinical trials

Interventional ClinicalTrials.gov studies with "Lamivudine" as an intervention, any sponsor and status, largest first.

All 737 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • foetal exposure during pregnancy2,040
  • drug resistance1,960
  • virologic failure1,960
  • drug interaction1,871
  • pathogen resistance1,774
  • viral mutation identified1,671
  • depression1,343
  • pyrexia1,279
  • drug ineffective1,165
  • anaemia1,126
  • pain1,122
  • nausea1,079

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,143
20051,218
20061,265
20071,049
20081,114
20091,084
2010763
2011671
2012757
2013670
2014805
20151,613
20162,262
20172,126
20182,122
20192,247
20202,541
20211,842
20221,853
20231,697
2024864
2025718
2026401

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Nov 16, 2026

    Epivir, Injection, 10 mg/1 mL (NDC 49702-205-48). The anticipated date that ViiV will cease distribution of the product is approximately May 14, 2027.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Epivir (Lamivudine)

2024 spending

$65K

Beneficiaries

30

186 claims

Per beneficiary

$2,165

$8.35 per unit

View as table
YearSpending
2020$166,660
2021$137,663
2022$118,172
2023$102,524
2024$64,963

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,044 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.